Medtronic (MDT) Cash & Equivalents (2013 - 2026)

Medtronic's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 7.5% year-over-year to $1.1 billion; the TTM figure through Jan 2026 stood at $1.1 billion (down 7.5% YoY), while the FY2025 annual figure was $2.2 billion, up 72.74% from the prior year.
• Cash & Equivalents came in at $1.1 billion for Q1 2026 at Medtronic, down from $1.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q4 2022 to a low of $1.1 billion in Q1 2026.
• A 5-year average of $2.1 billion and a median of $1.4 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 72.85% in 2023 and surged 72.74% in 2025, its largest moves.
• Medtronic's Cash & Equivalents stood at $4.8 billion in 2022, then sank by 72.85% to $1.3 billion in 2023, then rose by 6.33% to $1.4 billion in 2024, then decreased by 8.03% to $1.3 billion in 2025, then fell by 10.53% to $1.1 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.1 billion, $1.3 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison